Ana Ruiz-Garcia - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

Ana Ruiz-Garcia

Showing results (1-10 of 38) with videos related to

Pageof 4

Sort By:

Journal of Pharmaceutical Sciences|July 17, 2007

Pharmacokinetics in drug discoveryAna Ruiz-Garcia, Marival Bermejo, Aaron Moss, et al.

CPT: Pharmacometrics & Systems Pharmacology|January 15, 2021

Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participantsJoseph Chen, Brett Houk, Yazdi K Pithavala, et al.

Cancer Chemotherapy and Pharmacology|February 17, 2017

Effect of food on the bioavailability of palbociclibAna Ruiz-Garcia, Anna Plotka, Melissa O'Gorman, et al.

Journal of Pharmacokinetics and Pharmacodynamics|March 13, 2019

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphomaMay Garrett, Ana Ruiz-Garcia, Kourosh Parivar, et al.

Cancer Chemotherapy and Pharmacology|September 5, 2020

An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposureSwan Lin, Naveed Shaik, Geoffrey Chan, et al.

Journal of Clinical Pharmacology|September 25, 2020

Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic MalignanciesAna Ruiz-Garcia, Naveed Shaik, Swan Lin, et al.

Expert Review of Clinical Pharmacology|May 17, 2021

Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancerLuke K Fostvedt, Naveed Shaik, Giovanni Martinelli, et al.

Journal of Clinical Pharmacology|November 27, 2019

Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid TumorsSwan Lin, Naveed Shaik, Giovanni Martinelli, et al.

Clinical Pharmacology and Therapeutics|May 10, 2019

Pharmacokinetic/Pharmacodynamic Modeling to Support the Re-approval of Gemtuzumab OzogamicinLuke K Fostvedt, Jennifer E Hibma, Joanna C Masters, et al.

Pharmaceutics|April 11, 2020

Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of DacomitinibAna Ruiz-Garcia, Weiwei Tan, Jerry Li, et al.

Pageof 4

Search research articles

Showing results (1-10 of 38) with videos related to

Sort By:

Pageof 4

Journal of Pharmaceutical Sciences|July 17, 2007

Pharmacokinetics in drug discoveryAna Ruiz-Garcia, Marival Bermejo, Aaron Moss, et al.

CPT: Pharmacometrics & Systems Pharmacology|January 15, 2021

Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participantsJoseph Chen, Brett Houk, Yazdi K Pithavala, et al.

Cancer Chemotherapy and Pharmacology|February 17, 2017

Effect of food on the bioavailability of palbociclibAna Ruiz-Garcia, Anna Plotka, Melissa O'Gorman, et al.

Journal of Pharmacokinetics and Pharmacodynamics|March 13, 2019

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphomaMay Garrett, Ana Ruiz-Garcia, Kourosh Parivar, et al.

Cancer Chemotherapy and Pharmacology|September 5, 2020

An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposureSwan Lin, Naveed Shaik, Geoffrey Chan, et al.

Journal of Clinical Pharmacology|September 25, 2020

Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic MalignanciesAna Ruiz-Garcia, Naveed Shaik, Swan Lin, et al.

Expert Review of Clinical Pharmacology|May 17, 2021

Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancerLuke K Fostvedt, Naveed Shaik, Giovanni Martinelli, et al.

Journal of Clinical Pharmacology|November 27, 2019

Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid TumorsSwan Lin, Naveed Shaik, Giovanni Martinelli, et al.

Clinical Pharmacology and Therapeutics|May 10, 2019

Pharmacokinetic/Pharmacodynamic Modeling to Support the Re-approval of Gemtuzumab OzogamicinLuke K Fostvedt, Jennifer E Hibma, Joanna C Masters, et al.

Pharmaceutics|April 11, 2020

Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of DacomitinibAna Ruiz-Garcia, Weiwei Tan, Jerry Li, et al.

Pageof 4